Junshi Biosciences

Executive Summary

Junshi Biosciences is a leading Chinese commercial-stage biopharmaceutical company focused on oncology, immunology, and infectious diseases. Its flagship product, toripalimab, a PD-1 inhibitor, has been approved in China for multiple indications and is expanding globally. The company gained international recognition for its COVID-19 neutralizing antibody, etesevimab, developed with Eli Lilly. Junshi's robust pipeline includes novel monoclonal antibodies, bispecifics, and small molecules targeting unmet medical needs. With a strong R&D engine and strategic partnerships, the company is positioned for continued growth in both domestic and global markets. Key upcoming milestones include regulatory decisions for toripalimab in new geographies and clinical data readouts for pipeline candidates.

Upcoming Catalysts (preview)

• Q3 2026Toripalimab approval in EU for nasopharyngeal carcinoma80% success
• Q4 2026Clinical data readout for anti-BTLA antibody (TAB004/JS004) in solid tumors65% success
• 2026Partnership or licensing deal for etesevimab or next-generation COVID therapy70% success